Jeffrey D. Capello
CIK: 0001224108
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Oct 29, 2026NEOG
NEOGEN CORP
Exercise(M)Direct1.8K shares at avg. $12.21$22K - Oct 1, 2026NEOG
NEOGEN CORP
Award(A)Direct9.8K shares at avg. $12.24$120K - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.8K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.9K shares- - Jun 13, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2K shares- - Oct 27, 2025NEOG
NEOGEN CORP
Exercise(M)Direct1.8K shares at avg. $6.19$11K - Oct 27, 2025NEOG
NEOGEN CORP
Exercise(M)Direct2K shares at avg. $6.19$13K - Oct 23, 2025NEOG
NEOGEN CORP
Award(A)Direct19.8K shares at avg. $6.07$120K - Oct 7, 2025NEOG
NEOGEN CORP
Exercise(M)Direct2.1K shares at avg. $5.63$12K - Jun 20, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.1K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15.8K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.9K shares- - Jun 13, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2K shares- - Apr 22, 2025NEOG
NEOGEN CORP
Purchase(P)Direct20.7K shares at avg. $4.84$100K - Oct 28, 2024NEOG
NEOGEN CORP
Exercise(M)Direct1.8K shares at avg. $13.81$25K - Oct 24, 2024NEOG
NEOGEN CORP
Award(A)Direct6.1K shares at avg. $13.58$82K - Oct 7, 2024NEOG
NEOGEN CORP
Exercise(M)Direct2.1K shares at avg. $15.07$31K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 29, 2026 |  NEOG NEOGEN CORP | Exercise(M) | 1,776 | $12.21 | $21,685 | Direct |
| Oct 1, 2026 | NEOG NEOGEN CORP | Award(A) | 9,804 | $12.24 | $120,001 | Direct |
| Jun 18, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,816 | - | $0 | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 14,950 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,927 | - | - | Direct |
| Jun 13, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 1,976 | - | $0 | Direct |
| Oct 27, 2025 | NEOG NEOGEN CORP | Exercise(M) | 1,777 | $6.19 | $11,000 | Direct |
| Oct 27, 2025 | NEOG NEOGEN CORP | Exercise(M) | 2,025 | $6.19 | $12,535 | Direct |
| Oct 23, 2025 | NEOG NEOGEN CORP | Award(A) | 19,769 | $6.07 | $119,998 | Direct |
| Oct 7, 2025 | NEOG NEOGEN CORP | Exercise(M) | 2,071 | $5.63 | $11,660 | Direct |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,120 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 15,768 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,861 | - | - | Direct |
| Jun 13, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 1,977 | - | - | Direct |
| Apr 22, 2025 | NEOG NEOGEN CORP | Purchase(P) | 20,712 | $4.84 | $100,217 | Direct |
| Oct 28, 2024 | NEOG NEOGEN CORP | Exercise(M) | 1,776 | $13.81 | $24,527 | Direct |
| Oct 24, 2024 | NEOG NEOGEN CORP | Award(A) | 6,075 | $13.58 | $82,499 | Direct |
| Oct 7, 2024 | NEOG NEOGEN CORP | Exercise(M) | 2,070 | $15.07 | $31,195 | Direct |
1-18 of 18 transactions
About CAPELLO JEFFREY D
CAPELLO JEFFREY D (SEC CIK 0001224108) files insider reports with the SEC as Director of NEOGEN CORP (NEOG) and Director of AGIOS PHARMACEUTICALS, INC. (AGIO).
Signal8 holds 14 ownership filings by CAPELLO JEFFREY D, all Form 4s, filed between Oct 9, 2024 and Oct 30, 2026. Those filings report 18 transactions, from Oct 7, 2024 to Oct 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on CAPELLO JEFFREY D's filings is in LANSING, MI.
Recent filings by CAPELLO JEFFREY D
- Oct 29, 2026: Option exercise of NEOG shares (Form 4, code M).
- Oct 1, 2026: Grant or award of NEOG shares (Form 4, code A).
- Jun 18, 2026: Option exercise of AGIO shares (Form 4, code M).
- Jun 18, 2026: Grants or awards of AGIO derivative securities (2 lines, Form 4, code A).
- Jun 13, 2026: Option exercise of AGIO shares (Form 4, code M).
Other insiders filing for NEOGEN CORP (NEOG)
- Freels Joe B, Chief Commercial Officer
- Hastings Gregory S, VP, Animal Health
- Woteki Catherine E, Director
- RODRIGUEZ RAFAEL A, Director
- Burke Kevin M, Chief HR Officer
- Gupta Aashima, Director